Divi's Laboratories Ltd

In its latest note, the broker highlighted Divi's strong potential to emerge as a primary supplier, backed by ongoing capacity expansion. It also noted the addition of Orforglipron'Eli Lilly's promising oral GLP-1 candidate'to Divi's development pipeline. The report further anticipates additional rounds of capital expenditure as product volumes scale up through 2030. Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities. Divi's Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

In a regulatory filing on 18 April 2025, Divi's stated that the agreement pertains to the manufacturing and supply of advanced intermediates. While the name of the partner remains undisclosed due to a confidentiality clause, the company confirmed that the deal is international in scope and does not involve any upfront payment. Divi's expects meaningful revenue contribution from this partnership over the agreement's tenure. To support this new business, the company is planning a capacity expansion at its manufacturing facilities, with an estimated investment between Rs 650 crore and Rs 700 crore. The expansion will be fully funded through internal accruals. The agreement, while not falling under related party transactions, aligns with the company's strategy to broaden its custom synthesis offerings. Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities. Divi's Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

Divis Laboratories has signed a long term manufacturing and supply agreement with a global pharma company. Under the agreement, the company will manufacture and supply advance intermediates as per the commercial terms agreed between the parties. The company is planning to increase its manufacturing capacity with an estimated investment of Rs 650-700 crore to be funded from internal accruals. Powered by Capital Market - Live

Divi's Laboratories announced that G. Bala Kishore, serving as General Manager (EHS) of the Company, will be retiring effective from the close of business hours on 31 March 2025 and will cease to be Senior Management Personnel of the Company. Powered by Capital Market - Live

IndusInd Bank Ltd, Axis Bank Ltd, Gujarat State Petronet Ltd, Kaynes Technology India Ltd are among the other stocks to see a surge in volumes on BSE today, 12 March 2025.Divis Laboratories Ltd witnessed volume of 24583 shares by 10:47 IST on BSE, a 8.7 times surge over two-week average daily volume of 2824 shares. The stock dropped 0.39% to Rs.5,520.00. Volumes stood at 1781 shares in the last session.IndusInd Bank Ltd clocked volume of 33.57 lakh shares by 10:47 IST on BSE, a 5.52 times surge over two-week average daily volume of 6.08 lakh shares. The stock gained 4.67% to Rs.686.60. Volumes stood at 41.94 lakh shares in the last session.Axis Bank Ltd witnessed volume of 3.43 lakh shares by 10:47 IST on BSE, a 4.56 times surge over two-week average daily volume of 75288 shares. The stock dropped 1.08% to Rs.1,014.50. Volumes stood at 78020 shares in the last session.Gujarat State Petronet Ltd clocked volume of 93113 shares by 10:47 IST on BSE, a 3.86 times surge over two-week average daily volume of 24132 shares. The stock gained 4.85% to Rs.287.65. Volumes stood at 26057 shares in the last session.Kaynes Technology India Ltd saw volume of 1.17 lakh shares by 10:47 IST on BSE, a 3.75 fold spurt over two-week average daily volume of 31128 shares. The stock dropped 3.83% to Rs.4,140.65. Volumes stood at 18528 shares in the last session.Powered by Capital Market - Live

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 6093.9, up 2.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.66% on the day, quoting at 23197.45. The Sensex is at 76616.35, up 0.58%. Divis Laboratories Ltd has gained around 1.73% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 2.9% in last one month and is currently quoting at 21142.05, up 1.98% on the day. The volume in the stock stood at 4.67 lakh shares today, compared to the daily average of 4.35 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6111.6, up 1.98% on the day. Divis Laboratories Ltd is up 63.83% in last one year as compared to a 6.22% spurt in NIFTY and a 16.02% spurt in the Nifty Pharma index.The PE of the stock is 76.41 based on TTM earnings ending December 24.Powered by Capital Market - Live

Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 6146.65, up 0.38% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.38% on the day, quoting at 23607. The Sensex is at 77975.37, down 0.38%. Divis Laboratories Ltd has gained around 4.04% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 2.2 lakh shares today, compared to the daily average of 4.45 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6170.35, up 0.37% on the day. Divis Laboratories Ltd is up 64.71% in last one year as compared to a 7.64% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 78.43 based on TTM earnings ending December 24.Powered by Capital Market - Live

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 6074, up 3.23% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.05% on the day, quoting at 23606.2. The Sensex is at 78049.17, up 1.12%. Divis Laboratories Ltd has gained around 3.1% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 6.05% in last one month and is currently quoting at 21361.6, up 1.48% on the day. The volume in the stock stood at 10.02 lakh shares today, compared to the daily average of 4.03 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6101.05, up 2.96% on the day. Divis Laboratories Ltd is up 64.18% in last one year as compared to a 8.43% jump in NIFTY and a 18.5% jump in the Nifty Pharma index.The PE of the stock is 85.11 based on TTM earnings ending September 24.Powered by Capital Market - Live

Net profit of Divi's Laboratories rose 64.53% to Rs 589.00 crore in the quarter ended December 2024 as against Rs 358.00 crore during the previous quarter ended December 2023. Sales rose 25.01% to Rs 2319.00 crore in the quarter ended December 2024 as against Rs 1855.00 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2319.001855.00 25 OPM %32.0426.36 - PBDT825.00584.00 41 PBT726.00489.00 48 NP589.00358.00 65 Powered by Capital Market - Live

Total income grew by 23.13% year on year (YoY) to Rs 2,401 crore in the quarter ended 31 December 2024. Profit before tax for the quarter was at Rs 726 crore, up 48.47% from Rs 489 crore reported in the same period a year ago. Total expenses stood at Rs 1,675 crore in the third quarter of FY25, up 14.65% on YoY basis. Cost of material consumed was at Rs 1,021 crore (up 28.59% YoY) and employee benefit expenses stood at Rs 297 crore (up 10.82% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 10 crore as against a gain of Rs 18 crore posted in Q3 FY24. On nine-month basis, the company's net profit climbed 43.97% to Rs 1,529 crore on 22.25% rise in revenue from operations to Rs 6,775 crore in 9M FY25 over 9M FY24. Forex gain for the nine-month period amounted to Rs 38 crore as against a gain of Rs 32 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Powered by Capital Market - Live